ADC Deals Are Up 1900% in 2026 — Here's the Data

Twenty ADC deals closed between February and August 2026, up from exactly one in the prior six-month window — a 1,900% increase that represents the sharpest modality-specific deal surge we have tracked on Deal Benchmarks this year. The comparison periods are August 24, 2025 to February 24, 2026 (1 deal) versus February 24, 2026 to August 24, 2026 (20 deals). The driver is not a single catalyst but a convergence: next-generation ADC platforms have reached clinical proof-of-concept across solid tumors and hematologic malignancies simultaneously, and Big Pharma is racing to fill post-Enhertu, post-Padcev pipeline gaps before the window of differentiated targets closes.

The Data — ADC Deal Activity, Period over Period

The absolute numbers tell the story more clearly than the percentage. One deal in six months means the market was essentially frozen — likely a function of the ADC clinical setbacks and CMC headaches that plagued late 2025. Twenty deals in the subsequent window signals a regime change, not a rebound. This is a land grab.

What's Driving the Trend

Pipeline gaps at the top of the pyramid. AstraZeneca locked up the HER2-low opportunity with Enhertu. Pfizer consolidated its Nectin-4 position through the Seagen acquisition. That left GSK, Novartis, Roche, and Merck with meaningful ADC white space — and the competitive anxiety to fill it. When multiple $200B+ market-cap companies are bidding against each other for the same asset class, deal velocity and total deal values both spike. The Hansoh-GSK deal at $185M upfront and $1.7B total deal value (TDV) is a direct expression of this dynamic: GSK paid a premium because it had to.

Platform maturation beyond first-generation designs. The ADC licensing boom in 2026 is qualitatively different from the 2019–2021 wave. Licensors are bringing novel topoisomerase I inhibitor payloads, bispecific antibody–drug conjugates, and site-specific conjugation chemistries that address the tolerability and therapeutic-index problems of earlier constructs. Novartis's two simultaneous deals with Myricx Bio — totaling $2.6B in combined TDV — reflect a bet on differentiated linker-payload technology rather than a single clinical candidate. Pharma is buying platforms, not just molecules.

Capital markets as an accelerant. The biotech funding environment improved markedly in H1 2026, with crossover rounds and IPO windows reopening for oncology-focused companies. This gave ADC-focused biotechs the leverage to negotiate from strength rather than desperation. Several of these 20 deals are structured as co-development or opt-in partnerships, not fire-sale asset divestitures. Sellers have options, and they are using them to extract better economics — upfront cash, milestone density, and tiered royalties that were scarce 18 months ago.

Notable Deals

The Hansoh-GSK transaction is the headline deal and the clearest signal of where ADC licensing 2026 is headed. An $185M upfront for a China-origin ADC asset would have been unthinkable two years ago; GSK's willingness to pay reflects both competitive urgency and the clinical maturity of Hansoh's candidate. The 10.9% upfront-to-TDV ratio sits slightly below the median for oncology deals we track in Deal Benchmarks, suggesting GSK negotiated a milestone-heavy structure — reasonable given the remaining development risk.

The Myricx Bio–Novartis pairing is the more strategically significant signal. Two deals announced the same day, with a combined TDV of $2.6B, point to a platform-level partnership rather than a single-asset in-license. Novartis is building an internal ADC engine through external technology acquisition — a playbook similar to what AstraZeneca executed with Daiichi Sankyo but with a European biotech as the technology source. The undisclosed upfronts leave open questions about how much cash Myricx actually received versus equity or option-based structures.

Biocytogen's dual deals with Whitehawk, a less well-known buyer, illustrate that ADC deal activity in 2026 is not limited to the top five pharma companies. Mid-cap specialty oncology firms and newly capitalized biotech platforms are entering the ADC licensing market as acquirers, increasing competition for assets and pushing valuations upward. A $500M TDV for a preclinical or early-clinical ADC asset from Biocytogen represents aggressive pricing — or high conviction in the target biology.

What This Means for BD Teams Right Now

Sellers: this is the strongest ADC seller's market since 2021. If you are sitting on a differentiated ADC platform — novel payload class, bispecific conjugate architecture, or a validated target with limited competitive overlap — the data says your leverage is at or near its peak. Twenty deals in six months means buyers are moving fast and competing against each other. Use that to your advantage on upfront cash, milestone structure, and territorial splits. Do not accept option deals when you can get committed licenses.

Buyers: move now, but structure defensively. The 1,900% surge in ADC deal trends for 2026 is not a signal to wait. The best assets are clearing the market quickly. However, the sheer volume of deals means some will inevitably involve assets with undifferentiated biology or first-generation conjugation technology dressed up in next-gen language. Run your diligence hard on CMC scalability and therapeutic index data. Milestone-heavy structures with clear go/no-go gates remain the right defensive posture. Use Solidus to benchmark upfront-to-TDV ratios against the current cohort — the Hansoh-GSK deal at 10.9% is a useful anchor.

Deal structures gaining favor: co-exclusive territorial splits (ex-Greater China / Greater China), platform access deals with option-to-license provisions on specific targets, and milestone schedules tied to IND filing rather than just Phase 1 initiation. Structures losing favor: simple royalty-only deals, single-asset licenses without follow-on options, and anything that requires the licensor to fund clinical development beyond IND-enabling studies.

Benchmark your deal against current market rates using the Ambrosia calculator. The ADC market is moving fast — your term sheet should reflect where valuations are today, not where they were six months ago.